Abstract:Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UD V595E specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UD V595E specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UD V595E cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity. Several human cancers, including melanoma and colorectal carcinoma, harbor a specific mutation within the BRA F gene, termed V600E. This mutation causes aberrant activation of the MAPK signaling pathway that normally regulates critical processes including cell growth, survival and proliferation. An equivalent mutation occurs in 85% of canine urothelial carcinomas (UC), the most common canine urogenital cancer. We performed DNA sequencing analysis of 28 canine UC cases that do not bear this mutation, to identify alternative mutations that may contribute to tumor development. We identified 13 specimens (46% of cases) harboring short in-frame deletions clustering elsewhere within the BRAF gene, or within MAP2K1 , which also functions in the MAPK pathway. Importantly, equivalent deletions also occur in several human cancer subtypes, including certain leukemias and pancreatic carcinomas, and also Langerhans cell histiocytosis, resulting in structural disruption of the associated protein product. Critically, evidence is accumulating from human in vitro studies that tumors with BRAF or MAP2K1 in-frame deletions are susceptible to different classes of small-molecule inhibitors, compared to those with BRAF V600E. Progress has been limited by the relative rarity of the human cancer subtypes in which these aberrations occur. With more than 60,000 dogs developing UC each year in the US, our findings reveal a strategy to overcome these limitations. By performing parallel functional studies of BRAF and MAP2K1 in-frame deletions in canine UC we may greatly expand the volume of biological specimens and clinical data available for elucidating their significance for optimizing treatment protocols in both species.

Comparative analysis of whole exome sequencing kits for the canine genome

Genome sequence, comparative analysis and haplotype structure of the domestic dog

Comparative evaluation of four exome enrichment solutions in 2024: Agilent, Roche, Vazyme and Nanodigmbio

A new long-read dog assembly uncovers thousands of exons and functional elements missing in the previous reference

Performance comparison of four commercial human whole-exome capture platforms

Advancements in genetic analysis: Insights from a case study and review of next-generation sequencing techniques for veterinary oncology applications

Comprehensive Comparison of Three Commercial Human Whole-Exome Capture Platforms

Analyzing Performance of Twist Bioscience Exome Enrichment with Spike-in CNV Backbone Panels at Various Probe Densities Leveraging Golden Helix VS-CNV Analysis Software

Whole Genome 3D Blood Biopsy Profiling of Canine Cancers: Development and Validation of EpiSwitch Multi-Choice Array-Based Diagnostic Test.

An evaluation of copy number variation detection tools from whole-exome sequencing data.

Abstract 5665: Native nanopore sequencing of multiple tumor sites reveals genetic and epigenetic intra-tumor heterogeneity in canine osteosarcoma

Enhancing Variant Calling in Whole Exome Sequencing (WES) Data Using Population-Matched Reference Genomes

Whole genome analyses reveal significant convergence in obsessive-compulsive disorder between humans and dogs

Enhancing Variant Calling in Whole-Exome Sequencing Data Using Population-Matched Reference Genomes.

Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology

Genomic profiling of cell-free DNA from dogs with benign and malignant tumors

The wolf reference genome sequence (Canis lupus lupus) and its implications for Canis spp. population genomics

Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption

A novel canine reference genome resolves genomic architecture and uncovers transcript complexity

Genomic and Temporal Trends in Canine ExPEC Reflect Those of Human ExPEC

CanISO: a database of genomic and transcriptomic variations in domestic dog (Canis lupus familiaris)